I'm not exactly a stranger to the world of podcasting although I have concluded that while I might ask probing questions as an interviewer, I really don't have interest in hosting a podcast of my own. Still, over the years, I've been a guest on a few podcasts related to diabetes. For example, quite a number of years ago, I was a guest on the DiabetesPowerShow with host Charlie Cherry in which we just "talked shop" about issues related to diabetes. I'm not even sure if the archives of those shows even exist anymore, perhaps they might still be around on a place like the Internet Archive.
More recently than that, I was a guest on TWO of Diabetic Investor David Kliff's different podcasts in 2021 and 2022. For example, in September 2021, I was featured on the "Wacky World of Diabetes" podcast with David Kliff and that episode can still be found and listened to at https://diabeticinvestor.com/its-podcast-day/.
However, in June 2024, I happened to be a guest on TWO completely different diabetes podcasts. Both kind of happened by chance.
First up was an interview I did with Stacey Simms on her podcast Diabetes Connections with Stacey Simms. We had the conversation a few weeks earlier, but she released the episode in which I was interviewed as the guest on an episode on June 18, 2024. The topic of that particular episode was on the broader subject of the "Business of Diabetes", which was something I have long featured on this diabetes blog. The episode link for that episode can be found (and listened to) at https://diabetes-connections.com/the-business-of-diabetes-scott-strumellos-perspective-after-50-years-of-t1d/. For convenience, I am embedding a copy of that episode below.
Around the same time, I had published an article on something the Federal Trade Commission did which opened the doors to a whole bunch of less costly biosimilar GLP-1 inhibitors including those used for weight-loss (Novo Nordisk called its first-generation GLP-1 inhibitor for Type 2 medicine Victoza, and another version of the drug for obesity which was branded as Saxenda). I self-published my article entitled "FTC Challenge to Pharma's Improper FDA Orange Book Patent Listings Poised to Open the Door to Cheaper Weight-Loss Drugs" on LinkedIn on May 9, 2024 which can be seen at https://www.linkedin.com/pulse/ftc-challenge-pharmas-improper-fda-orange-book-patent-scott-strumello-h6ede/ (I originally posted it on my blog as a first draft, but the LinkedIn version was edited to be more concise, so I went back my blog post and also edited it here which you see on a blog at https://blog.sstrumello.com/2024/04/ftc-again-polices-fdas-laziness-with.html — the article on my blog is now exactly the same as the more concise article which I published on LinkedIn).
One of the reasons I opted to self-publish an article about GLP-1 inhibitors being sold as weight-loss drugs is because corporate media had completely missed the story, and I wanted to ensure an important story was covered, so I took matters into my own hands. Most of the corporate media stories about weight-loss drugs are hyperbolic nonsense with stupid headlines on topics as idiotic as "Ozempic Babies" (see one at https://www.usatoday.com/story/life/health-wellness/2024/04/17/ozempic-withdrawal-surprise-pregnancy/73340586007/ if you need convincing) while ignoring the elephant in the room: the price of those drugs.
Anyway, my LinkedIn article had caught the attention of another diabetes podcaster, specifically Scott Benner who hosts the Juicebox Podcast. Scott asked if I would talk to him about my LinkedIn article on his podcast, so a few weeks later, he reached out to me to talk about my article. He released the episode on June 12 (or 13), 2024 in which he named it Episode #1224 "Orange Book Chronicles". The episode link is at https://www.juiceboxpodcast.com/episodes/jbp1224. Again, for your convenience, I have embedded the episode below so you can listen to it here.
Writer, speaker, brother, son, friend, spouse, advocate for people with autoimmune (type 1) diabetes, thinker, dreamer. Reading and writing is becoming a lost art, but we can learn a lot from reading the medical and scientific literature before drawing conclusions. The press publishes abbreviated facts to fit into limited space, I don't mince words or omit facts.
Download a Dexcom manufacturer coupon to save $200 per 30-day supply of sensors (and an additional $200 on each 3-month transmitter on the G6 model).
Get Freestyle Libre e-Savings Voucher
If you're commercially insured and asked to pay more than $75 for two Freestyle Libre 3 sensors, call Abbott customer care at 1-855-632-8658 (M-F from 8-8 ET) to ask for an eSavings voucher. Abbott manufacturer vouchers expire at the end of each calendar year and patients must call each January to request a new voucher for the new year.
Eversense PASS Savings Program
Eligible individuals can experience EVERSENSE E3 CGM for only $99, now and in the future. That includes the patient's initial and ongoing sensor and sensor/transmitter combinations. The Eversense PASS Program will be applied to eligible patients who purchase Eversense E3 CGM directly through a participating Strategic Fulfillment Partner. Patients will be informed of eligibility by the Strategic Fulfillment Partner when discussing out-of-pocket costs. Offer does not apply to the insertion and removal procedures.
Xeris Gvoke Hypopen
Eligible commercially insured patients may pay as little as $25 with a manufacturer Copay Card.
Call to request your Zegalogue® Savings Offer
If you have commercial insurance, such as insurance you receive through an employer, depending on your insurance coverage and out-of-pocket responsibility, you may pay $35 or $99 for each one-pack prescription for up to 48 months from date of Savings Offer activation. Call 1-833-992-3299 to request a Zegalogue® Savings Offer.
Lilly Insulin Value Program
Sanofi ValYOU Insulins Savings Program
NovoCare Manufacturer Discount Coupons
My Biocon Biologics Savings Card Program
For more info., contact Biocon Biologics, Inc. by telephone at 844-348-3404 or by email at contact.us@bioconbiologics.com
Afrezza Savings Program
If you have insurance, you may be eligible for the Afrezza Savings Card that lets you pay as little as $35 for your prescription. To obtain your Afrezza Savings Card, sign up at the company's website at to register. You will receive your card via email or you can print a card. https://afrezza.com/savings-program/
No comments:
Post a Comment